BFI Co., LLC, which holds roughly one-tenth of Phibro Animal Health Corp's outstanding Class A common stock, executed a block of sales totaling 14,080 shares on March 30 and March 31, 2026. The transactions generated approximately $756,833 in proceeds, with execution prices recorded between $53.5415 and $54.3533 per share.
The dispositions were carried out pursuant to a Rule 10b5-1 trading arrangement that BFI Co., LLC adopted on December 11, 2025. Following the March trades, the entity directly retains ownership of 38,120 shares of Phibro Animal Health Corp Class A common stock.
Jack Bendheim, who serves as President, Chief Executive Officer and a director of Phibro Animal Health Corp, exercises voting and dispositive authority over BFI Co., LLC and therefore may be considered to share voting and investment power with respect to the shares held by that entity. Mr. Bendheim has stated that he disclaims beneficial ownership of those securities, except to the extent of any pecuniary interest he may have. In addition to the shares attributed to the entity, Bendheim directly holds 16,840 shares.
The timing of the sales coincides with Phibro Animal Health trading near its 52-week high of $57.62. The stock has risen roughly 162% over the past 12 months, according to the information provided.
Market analysis cited in the reporting indicates that, on InvestingPro's metrics, PAHC presently appears overvalued relative to its Fair Value. The platform is referenced as offering additional analytical items such as ProTips and expanded financial metrics for investors seeking further detail.
Separately, Phibro Animal Health released fiscal second-quarter 2026 financial results that exceeded consensus estimates. The company reported earnings per share of $0.87, above the forecast of $0.68, representing an earnings surprise of 27.94%. Revenue for the quarter totaled $373.9 million, surpassing the expected $355.24 million by 5.25%.
Those quarterly results were highlighted in the reporting as indicators of the company's performance during the period. The sales by BFI Co., LLC, the ownership disclosures related to Jack Bendheim, the InvestingPro valuation note, and the fiscal Q2 2026 results together form the factual basis for investor and market interest in Phibro Animal Health at this time.